Podcasts about Renal cell carcinoma

In this JCO Precision Oncology Article Insights episode, Miki Horiguchi summarizes two articles: “Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening,” by Dr. Kate I. Glennon et al. published on August 01, 2024, and "Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?” by Dr. Salvador Jaime-Casas, et al. published on August 01, 2024. TRANSCRIPT Miki Horiguchi: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host Miki Horiguchi, an ASCO Journal's Editorial Fellow. Today, I'll be providing summaries of the article titled, "Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening,” by Dr. Kate Glennon and colleagues. In the accompanying editorial titled, “Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?” by Dr. Salvador Jaime-Casas and colleagues. Renal cell carcinoma (RCC) exhibits distinct clinical characteristics across its histological subtypes. Clear cell RCC accounts for approximately 75% of cases while the remaining non-clear cell RCC encompasses a diverse group of histology. Although a family history has been known to double the risk for RCC, genetic susceptibility, particularly across different histological subtypes and defined operations, has not been investigated well. Dr. Glennon and colleagues sought to identify risk genes for RCC within the Canadian population and investigate their clinical significance in comparison to cancer-free control populations. The authors conducted targeted sequencing of 19 RCC related genes and 27 cancer predisposition genes for 960 RCC patients in Canada. DNA samples were collected through the Ontario Tumour Bank between 2005 and 2019. For comparisons across histological subtypes, the cohort was divided into 759 patients with clear cell RCC and 201 patients with non-clear cell RCC, including all histological subtypes other than clear cell RCC. Non-cancer control data were obtained from a publicly available database which included over 118,000 cases from the European population. A total of 39 different germline pathogenic variants were identified in 56 patients representing 5.8% of the Canadian cohort. There was no significant difference in the overall number of germline pathogenic variants between the two groups. The most commonly identified germline pathogenic mutations were CHEK2, ATM/BRCA2 and MITF in the clear cell RCC group, and FH and CHEK2 in the non-clear cell RCC group. Compared to the non cancer control data, germline pathogenic variants in CHEK2 and ATM were significantly associated with an increased risk of developing clear cell RCC, while those in FH were significantly associated with non clear cell RCC. According to the bivariate association analysis between the presence of germline pathogenic variants and clinical characteristics, patients with metastatic RCC were strongly associated with pathogenic variants in BRCA1, BRCA2, and ATM. No other significant associations were observed. The authors then evaluated variations in germline pathogenic variants among RCC patients across the world using similar studies conducted in Canada, Japan, the United Kingdom, and the United States. Specifically, they compared the gene burden for significantly mutated genes in each of the cohorts against all other cohorts combined. Compared to the other cohorts, RCC patients from Japan were enriched for pathogenic variants in TP53 and depleted for pathogenic variants in CHEK2. The United States cohorts showed higher frequencies of patients with pathogenic variants in BAP1 and FH genes compared to other cohorts. In contrast, RCC patients from Canada and the United Kingdom were not enriched for any specific genes when compared with the other cohorts. After characterizing germline susceptibility to RCC, the authors evaluated how many of the RCC patients in the Canadian cohort did not meet existing referral criteria for genetic screening based on current clinical guidelines, aiming to help refine these guidelines. Among the 56 RCC patients with identified germline pathogenic variants in the Canadian cohort, 73% did not meet the referral criteria for genetic screening under current Canadian guidelines. The authors also applied the UK guidelines and the US American College of Medical Genetics guidelines to the same 56 RCC patients. Under these criteria, 80% and 64%, respectively, were not eligible for genetic screening. In an exploratory analysis, the authors examine the impact of raising the Asia onset threshold from less than 45 years to less than 50 years. This revision captured an additional five patients with pathogenic variants. In addition to more inclusive genetic screening guidelines, the study results suggest that expanding the current list of genes to include additional relevant genes such as BRCA1, BRCA2, CHEK2 and ATM could help identify more RCC patients who are affected by rare germline pathogenic variants in Canada. The authors concluded that these revisions would enable the identification of a higher number of at-risk patients and improve the management of RCC patients. In the associated editorial accompanying this research article, Dr. Salvador Jaime-Casas and colleagues emphasized that the findings from Dr. Glennon and colleagues' study are particularly worrisome as most RCC patients with incidental pathogenic variants are not being referred for genetic screening. Building on results from previous studies, the authors suggested the need to revisit and update the current screening guidelines for RCC patients. The authors also highlighted findings from other studies showing the prevalence of pathogenic variants in CHECK2, BRCA1, and BRCA2 at up to 6% in RCC patients and 11% in upper tract urothelial carcinoma patients. They noted that these rates are comparable to those of ovarian cancer and pancreatic cancer, which already have universal screening guidelines. The authors also discuss some challenges. While the prevalence of pathogenic variants is crucial for evaluating the impact of germline genetic testing, it's only one factor in devising screening guidelines for RCC and urothelial carcinoma. They emphasize the need for robust clinical trials to evaluate therapeutics targeting these pathways, as well as the importance of characterizing incidental pathogenic variants to guide patient selection for these trials. Thank you for listening to JCO Precision Oncology Article Insights and please tune in for the next topic. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Listen as Dr. London Smith (.com) and his producer Cameron discuss Renal Cell Carcinoma as they share tips on starting a cult. Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Produced by: Dylan Walker Created by: London Smith

Murray was living in the Middle East when in 2012 he was diagnosed with renal cell carcinoma. Before long the cancer had spread to his lungs, abdomen and liver and he was offered palliative care. After a near fatal stay in the ICU, Murray received some divine guidance which led him to begin to heal and a couple of weeks later, his scan indicated the cancer had essentailly disappeared. He believes that his overindulgent lifestyle, combined with a highly stressful job in a strong "blame culture" environment contributed to his diagnosis. It took Murray a while to grasp the fact that the cancer was actually an alarm bell telling him to sort his life out and to start putting health and well-being first. Today, Murray considers the cancer a blessing that made him change his lifestyle and today 6 years later he is still cancer free.” To connect with Murray... WEBSITE: WWW.KICKTHETERMINALOUTOFCANCER.CO.UK Kick the Terminal Out of Cancer Book written by his wife Mags Cluley FACEBOOK INSTAGRAM ______ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube

In this episode, two experts in the field of kidney cancer, Dr Benjamin Garmezy and Dr Vaishampayan, will present hypothetical case studies that represent typical patients seen with advanced renal cell carcinoma (aRCC) in practice. The faculty will discuss treatment approaches, adverse event management, and which factors to consider during the treatment decision-making process. Listeners to this vodcast audio, or views of the vodcast on the Oncology and Therapy website will get a better understanding of clinical trial outcomes related to an immuno-oncology (IO) agent and tyrosine kinase inhibitor (TKI) combination, such as axitinib plus pembrolizumab, that they can apply to their practice immediately. In addition, they will gain real-world insight into how experts approach the treatment of patients with aRCC and, more importantly, therapy management.   This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00305-3. All conflicts of interest can be found online. This podcast is intended for medical professionals.    Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.  

Renal cell carcinoma has an estimated lifetime prevalence of 2.3% for men and 1.3% for women in the US. Affected patients in early stages can have >94% cancer-specific survival. Author William Y. Kim, MD, of the University of North Carolina joins JAMA Associate Editor David L. Simel, MD, MHS, to discuss the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma. Related Content: Renal Cell Carcinoma

Welcome to the Sterile Technique Podcast! It's the podcast about Surgical Technology. Whether you are a CST or CSFA, this podcast helps you earn CE credits and improve your surgery skills in the OR. This episode discusses the cover article of the April 2017 issue of The Surgical Technologist, which is the official journal of the Association of Surgical Technologists (AST). The article is titled, "Using Open Partial Nephrectomy as Treatment for Renal Cell Carcinoma". "Scrub in" at steriletpodcast.com and on Twitter, @SterileTPodcast (twitter.com/SterileTPodcast). This podcast is a Dybas Media production. Sound effects adapted from GarageBand and sindhu.tms at https://freesound.org/people/sindhu.tms/sounds/169065/ and licensed courtesy of https://creativecommons.org/licenses/by-nc/3.0/.

Visit learnAMAstyle.com to uplevel your writing and editing skills with free downloads on medical writing and editing. The FDA has approved vonoprazan (Voquenza) for treating non-erosive gastroesophageal reflux disease (GERD) in adults. Vonoprazan is an oral potassium-competitive acid blocker (PCAB) already approved for erosive esophagitis and Helicobacter pylori infection. PCABs are a new class of medicines that inhibit stomach acid secretion. Non-erosive GERD is the most common form of GERD, affecting around 45 million US adults, with about 15 million treated with prescription medication annually. Many patients remain dissatisfied with existing treatments, experiencing symptoms that affect their quality of life. The approval of vonoprazan was based on the Phalcon-Nerd-301 study, a Phase 3 trial showing it significantly reduced heartburn episodes and provided more heartburn-free days and nights compared to placebo. The trial included 772 adults with frequent heartburn, demonstrating vonoprazan's effectiveness over placebo. The FDA has granted fast track designation to ADI-270 for metastatic or advanced clear cell renal cell carcinoma (ccRCC) in patients who previously received an immune checkpoint inhibitor and a VEGF inhibitor. ADI-270 is a CD70-targeted gamma delta CAR T-cell therapy designed to enhance resilience to the tumor microenvironment. A phase 1/2 trial will evaluate ADI-270 in patients with confirmed ccRCC who have been previously treated. The primary endpoints are the incidence of dose-limiting toxicities and the proportion of treatment-emergent adverse effects. The FDA has granted Fast Track and Regenerative Medicine Advanced Therapeutic (RMAT) designations to Lomecel-B, an investigational MSC therapy for Alzheimer's disease (AD). Lomecel-B aims to address neurodegeneration in AD and showed positive results in the CLEAR MIND Phase 2a trial. Visit learnAMAstyle.com to uplevel your writing and editing skills with free downloads on medical writing and editing.

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles, including the following topics: Introduction (0:00) Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27) CME information and select publications

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma.

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here. (https://www.researchtopractice.com/PostASCO2024/RCC)

Jeff Blumenfeld, a dynamic marketing executive with a career spanning over five decades, has worked with leading corporations such as Pepsi, Michelin, and Virgin Atlantic. He is the founder of Blumenfeld and Associates, author of "Get Sponsored" and "Travel With Purpose" and member of the International Skiing History Association and The Explorers Club. He brings his inspiring journey to the Legacy Leaders Show, which underscores the crucial role of community support in overcoming challenges. As a 72, Jeff's story is a testament to resilience, innovation, and the power of advocacy. Diagnosed with Renal Cell Carcinoma in 2009, Jeff faced a challenging battle, culminating in a kidney transplant in November 2023. His innovative campaign for a donor, involving media appearances and social media outreach, showcases his resilience and marketing expertise. Now a passionate Kidney Advocate, he speaks at NKF workshops and serves on Colorado's Kidney Disease Prevention and Education Task Force. Join us for this new episode of the Legacy Leaders Show to hear Jeff Blumenfeld's inspiring story of overcoming adversity and his dedication to kidney advocacy.

Jeff Blumenfeld, a dynamic marketing executive with a career spanning over five decades, has worked with leading corporations such as Pepsi, Michelin, and Virgin Atlantic. He is the founder of Blumenfeld and Associates, author of "Get Sponsored" and "Travel With Purpose" and member of the International Skiing History Association and The Explorers Club. He brings his inspiring journey to the Legacy Leaders Show, which underscores the crucial role of community support in overcoming challenges. As a 72, Jeff's story is a testament to resilience, innovation, and the power of advocacy. Diagnosed with Renal Cell Carcinoma in 2009, Jeff faced a challenging battle, culminating in a kidney transplant in November 2023. His innovative campaign for a donor, involving media appearances and social media outreach, showcases his resilience and marketing expertise. Now a passionate Kidney Advocate, he speaks at NKF workshops and serves on Colorado's Kidney Disease Prevention and Education Task Force. Join us for this new episode of the Legacy Leaders Show to hear Jeff Blumenfeld's inspiring story of overcoming adversity and his dedication to kidney advocacy.

Dr Vivek Narayan is an Assistant Professor of Medicine at Hospital of the University of Pennsylvania, Philadelphia, US. View the entire webinar here: https://www.radcliffecardiology.com/video-index/renal-cell-carcinoma-and-vegf-tki-cardiovascular-toxicity

Featuring perspectives from Dr Eric Jonasch and DR Brian Rini, including the following topics. Introduction (0:00) Current Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Dr Rini (5:11) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr Jonasch (38:52) CME information and select publications

✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2312695#ap0✅Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial https://www.annalsofoncology.org/article/S0923-7534(24)00105-4/fulltext✅Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrumhttps://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00185-X✅Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimabhttps://www.jtocrr.org/article/S2666-3643(24)00045-6/fulltext✅The Lancet Breast Cancer Commissionhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00747-5/fulltext✅Top advances of the year: Uterine cancerhttps://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35321

CME credits: 1.00 Valid until: 18-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/applying-novel-strategies-to-the-treatment-of-advanced-renal-cell-carcinoma/16392/ Learn about evolving standards in the care of patients with advanced renal cell carcinoma in this on-demand webcast capturing a live presentation by Mary Weinstein Dunn, MSN, NP-C, OCN, RN.=

Senior Editor Owen Stretton talks to Professor Shankar Shiva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery's new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.Continue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma

Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma

Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma

Sumanta Pal, MD, discusses the treatment of patients with metastatic renal cell carcinoma (mRCC), management of cardiovascular toxicities associated with therapies for mRCC, and the future treatment landscape of mRCC. Moderated by Sarah Waliany, MD, MS.

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Renal Cell Carcinoma — Thomas E Hutson, DO, PharmD (6:19) Urothelial Bladder Cancer — Guru P Sonpavde, MD (34:59) CME information and select publications  

Check out this week's QuadCast as we highlight some of the most important data from ASTRO 2023, including SBRT for Renal Cell Carcinoma, SRS for small cell, RT instead of transplant for relapsed Hodgkin lymphoma, and more!

BUFFALO, NY- September 20, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 15, 2023, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma.” In their new editorial, researchers Kuniko Horie and Satoshi Inoue from Saitama Medical University and Tokyo Metropolitan Institute for Geriatrics and Gerontology discuss renal cell carcinoma (RCC) — a major adult kidney cancer, which is often incidentally discovered as an asymptomatic disease on imaging in the developed countries. RCC has the most fatal disease among urological cancers, as a recent 5-year relative survival rate in the U.S. (2009–2015) is less than 80%. While RCC is known as a cancer resistant to chemo- and radio-therapies, the prognosis of RCC has been remarkably improved after the clinical application of tyrosine kinase inhibitors (TKIs) and immunotherapy. The rationale for the efficacy of TKIs in RCC is mainly based on the angiogenetic status, particularly in clear cell RCC (ccRCC) that is the most common type of RCC (70–75% of RCC), in which the loss of function mutation of Von Hippel-Lindau (VHL) tumor suppressor gene activates hypoxia inducible factor (HIF) and vascular endothelial growth factor (VEGF) pathways. The first-line TKIs that predominantly target VEGF receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) (e.g., sunitinib and sorafenib) have been clinically used since late 2000s, and the second-line TKIs such as cabozantinib, which targets more receptor tyrosine kinases including MET and TAM kinases as well as VEGFR, have been further applied to the treatment of advanced RCC since early 2010s in which the first-line TKIs are ineffective. “In our recent study, we established a panel of patient-derived ccRCC spheroid cultures with the enhancement of cancer stemness gene signature including DPP4 [9]. Focusing on TKI sunitinib sensitivity, we demonstrated that DPP4 inhibition increased sunitinib efficacy in DPP4-high RCC spheroids and DPP4 was upregulated in sunitinib-resistant RCC cells.” DOI - https://doi.org/10.18632/oncotarget.28463 Correspondence to - Satoshi Inoue - sinoue07@gmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28463 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, renal cell carcinoma (RCC), tyrosine kinase inhibitor (TKI), Dipeptidyl peptidase IV (DPP4), drug resistance, drug repurposing About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

CME credits: 1.00 Valid until: 30-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-up-with-the-rapid-emergence-of-strategies-for-advanced-renal-cell-carcinoma/15865/ Watch this educational activity to learn about the latest guideline-recommended first-line and later-line treatments for advanced renal cell carcinoma (RCC), as well as strategies to manage adverse (AEs) events of novel therapies. =

Featuring an interview with Dr Rana R McKay, including the following topics: Prostate Cancer (0:00) Renal Cell Carcinoma (22:58) Urothelial Bladder Cancer (52:18) CME information and select publications

In this episode, Jay and Angi talk about how precious time is. Stop wasting it on frivolous things!  No Regrets! This week's Do Hard Things Spotlight winners are Roy and Carol Mealer. Roy and Carol Mealer are "overlanders" from Sherman Texas. They met and have been traveling the U.S. over the past 3 years in their Jeep. Roy and Carol and I had a wonderful patriotic wedding on July 5th surrounded by family and friends in the Bridger-Teton NF. 4 Day's later, Roy was diagnosed with Renal Cell Carcinoma. He is now in the fight of his life.  They could use some help if you are able. Wristband fundraiser details:1 for $53 for $125 for $20Flat rate shipping $4#Roystrong Methods for submitting bracelet payments or other donations:Venmo: @Roy-Mealer-1Zelle: Carolgilberthr@gmail.com Paypal: Carolgilberthr@gmail.com CashApp: $CarolgilberthrFundraiser by Roy Mealer : Help Roy Mealer Beat Cancer (gofundme.com)Welcome to the Do Hard Things Podcast with your host Jay Tiegs, Are you ready to amplify and improve your life? Then you are in the right place. On this podcast we have unfiltered conversation with inspiring people who take on challenges and share with us, the wisdom from their journey. We talk about how doing hard things adequately enable all of us to deal with life's struggles and challenges and ultimately improve the quality of our lives. Do Hard Things Link Tree: https://linktr.ee/dohardthings

Please visit answersincme.com/XJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and urology discuss guideline-recommended systemic treatment options and strategies to optimize long-term care for patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of VHL disease-associated RCC; Describe the clinical impact of current guideline-recommended systemic treatment options for VHL disease-associated RCC; and Identify strategies to optimize long-term care for patients with VHL disease-associated RCC.

Featuring perspectives from Dr David F McDermott and Dr Sumanta Kumar Pal, including the following topics: Introduction (0:00) ASCO 2023 (1:35) Management of Advanced Renal Cell Carcinoma (RCC) (17:19) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC (38:13) CME information and select publications

Featuring perspectives from Dr David F McDermott and Dr Sumanta Kumar Pal, moderated by Dr Neil Love.

Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Thomas Hutson, MD!

In this podcast, Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial: a prospective, multicenter, single arm phase II trial evaluating efficacy and safety of cabozantinib for patients with metastatic renal cell carcinoma progressed after one line of treatment based on immune-checkpoints inhibitors.

Listen in to this podcast recorded live at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Bradley McGregor, MD!

This week, Matt Iseman shares how he made his journey from an Ivy League education and medical degree to being known as one of American Ninja Warrior's beloved hosts. In this episode you will learn: How to connect with your audience by introducing your personality and showing them that they can be comfortable. Learning that you are not competing with others but competing with the best version of yourself.  Remember to have grace with yourself and stop comparing yourself to others. Say yes to every opportunity you get no matter how small.  You have to put the “reps” in to get better and learn what works for you. About Matt Iseman: Life is short, do what makes you happy.” That's the advice that Matt got from his Dad - a world renowned physician - when Matt quit medicine to pursue stand-up comedy. And those words still guide Matt today. He talks ninjas, tells jokes around the world and, in general, proves laughter is the best medicine. Perhaps best known as the host of the FOUR TIME Emmy nominated “American Ninja Warrior” and being named the newest Celebrity Apprentice, the Boston Globe has said of Matt, “The best part about American Ninja Warrior, hands down, is when bro-host Matt Iseman roars the show's title.” He also helms the latest spinoff, American Ninja Warrior Junior, on Universal Kids (it's their highest rated show ever) and he headed up the spinoff, “ANW: Ninja vs Ninja” on the USA Network. Matt hosted Evel Live on History, the highest rated cable special of 2018 and makes regular visits to the Today Show. He also hosts Live Rescue on A&E following the life & death everyday heroics of First Responders. His ongoing battle with Rheumatoid Arthritis transformed him into a strong supporter of the Arthritis Foundation, the charity he's represented while winning Celebrity Apprentice. Yes, Arnold Schwarzenegger considers him a celebrity. For his work over the past decade and a half, Matt was named the 2018 “Arthritis Warrior of the Year.” And his battle with Renal Cell Carcinoma has made him a spokesperson for the American Cancer Society. He still serves as the Apprentice to the Boss, Arnold Schwarzenegger, hosting the Arnold Strongman Classic and helping him raise millions of dollars for the After School All Stars. Matt also supports the American Cancer Society, the Cystic Fibrosis Foundation and serves as an Ambassador for the Armed Services Arts Partnership. You can connect with Matt in the following ways: Website: https://www.mattiseman.com/ Facebook: https://www.facebook.com/mattiseman Twitter: https://twitter.com/mattiseman YouTube:https://www.youtube.com/user/mattisemanlive Instagram: https://www.instagram.com/mattiseman/ You can connect with Laura in the following ways: LinkedIn: https://www.linkedin.com/in/drlaurasicola LinkedIn Business Page: https://www.linkedin.com/company/vocal-impact-productions/ YouTube: https://www.youtube.com/c/VocalImpactProductions Facebook: Vocal Impact Productions Twitter: @LauraSicola Instagram: @VocalImpactProductions Website: https://vocalimpactproductions.com/ Laura's Online Course: virtualinfluence.today See omnystudio.com/listener for privacy information.See omnystudio.com/listener for privacy information.

Proceedings from our Year in Review webinar on the management of renal cell carcinoma and bladder cancer. Featuring perspectives from Dr Matthew Milowsky and Prof Thomas Powles, moderated by Dr Neil Love.

Featuring perspectives from Dr Matthew Milowsky and Prof Thomas Powles, including the following topics: •      Introduction (0:00) •      Renal Cell Carcinoma (3:23) •      Urothelial Bladder Cancer (35:05) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Renal Cell Carcinoma and Bladder Cancer — Faculty Presentation 2: Urothelial Bladder Cancer — Matthew Milowsky, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Renal Cell Carcinoma and Bladder Cancer — Faculty Presentation 1: Kidney Cancer — Prof Thomas Powles CME information and select publications

Featuring perspectives from Prof Laurence Albiges, Dr Toni Choueiri and Prof Thomas Powles, moderated by Dr Brian Rini, including the following topics: •      Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors for Nonmetastatic Renal Cell Carcinoma (RCC) — Prof Powles  o   Introduction (0:00) o   Case: A woman in her early 60s after left nephrectomy (T3aN0M0 clear cell carcinoma) — Swati Vishwanathan, MD (1:39) o   Cases: A man in his early 50s develops renal dysfunction after 2 cycles of adjuvant pembrolizumab for RCC and a man in his late 60s with Stage III clear cell RCC (ccRCC) discontinues adjuvant pembrolizumab due to severe musculoskeletal pain and joint swelling — Justin Peter Favaro, MD, PhD and Priya Rudolph, MD, PhD (6:05) o   Faculty presentation: Prof Powles (11:03) •      Evidence-Based Selection of First-Line Therapy for Metastatic RCC — Dr Choueiri  o   Case: A man in his early 70s with metastatic RCC enrolls on the PDIGREE trial and receives nivolumab/ipilimumab without response followed by cabozantinib — Helen H Moon, MD (21:32) o   Cases: A man in his early 70s receives ipilimumab/nivolumab for widely metastatic RCC and develops autoimmune hepatitis and a man in his early 60s with metastatic ccRCC receives ipilimumab/nivolumab followed by nivolumab with response but develops hypothyroidism and hypoadrenalism — Victoria Giffi, MD and Philip L Brooks, MD (25:33) o   Faculty presentation: Dr Choueiri (36:38) •      Treatment Options for Relapsed/Refractory RCC — Dr Rini  o   Case: A woman in her early 60s with metastatic ccRCC receives lenvatinib/pembrolizumab but develops difficult-to-manage hypertension — Eric H Lee, MD, PhD (46:04) o   Case: A woman in her mid 60s with metastatic ccRCC and somatic VHL gene mutation receives ipilimumab/nivolumab and develops a solitary brain metastasis — Sunil Gandhi, MD (52:36) o   Faculty presentation: Dr Rini (57:54) •      Management of RCC Among Special Patient Populations — Prof Albiges  o   Case: A man in his late 60s with Waldenström macroglobulinemia and metastatic papillary RCC receives first-line ipilimumab/nivolumab followed by nivolumab but develops disease progression, including brain metastases — Nikesh Jasani, MD (1:07:58) o   Case: A woman in her early 70s with a history of psoriatic arthritis develops metastatic ccRCC, receives pembrolizumab/axitinib and develops elevated liver function tests — Georges Azzi, MD (1:12:38) o   Faculty presentation: Prof Albiges (1:18:45) CME information and select publications

Andrew reads our renal cell carcinoma article to Matt Morgan who adds his expert insights to level-up your radiology knowledge! Find the article ► https://radiopaedia.org/articles/renal-cell-carcinoma-1 Radiopaedia 2023 Virtual Conference ► https://radiopaedia.org/courses/radiopaedia-2023-virtual-conference Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Andrew's Twitter ► https://twitter.com/drandrewdixon Frank's Twitter ► https://twitter.com/frankgaillard Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

In this episode, we review the high-yield topic of Renal Cell Carcinoma from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Featuring an interview with Dr Toni Choueiri, including the following topics: Case: A woman in her early 70s with a large kidney tumor and multiple pulmonary nodules (0:00) Case: A woman in her early 60s diagnosed with metastatic clear cell renal cell carcinoma (RCC) (12:52) Approach to adjuvant treatment for RCC (16:14) Examining differences between PD-1 and PD-L1 inhibitors (20:09) Management of non-clear cell RCC (24:10) Challenges in identifying patients with RCC who are more likely to benefit from immune checkpoint inhibitors (28:22) Mechanisms of action of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (30:31) Future directions in the care of patients with RCC (36:24) CME information and select publications

Featuring a slide presentation and related discussion from Dr Toni Choueiri, including the following topics: Evolution in the management of renal cell carcinoma (RCC) (0:00) Adjuvant therapy for intermediate- or high-risk RCC (1:52) Front-line therapy for patients with metastatic RCC (8:39) New agents for the treatment of relapsed or refractory RCC (16:24) Mechanism of action and efficacy of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (19:56) CME information and select publications

Dr Toni Choueiri from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in the care of patients with renal cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRCC22).

Featuring a discussion on recent advances in the treatment of renal cell carcinoma with Dr Toni Choueiri, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in renal cell carcinoma. Featuring perspectives from Prof Thomas Powles, including the following topics: Optimal First-Line Therapy for Patients with Metastatic RCC (0:00) Treatment Approaches for Relapsed/Refractory Metastatic RCC (18:42) CME information and select publications

Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.22.27971  Aruj Chawla, DO discusses how a CT-based algorithmic approach provides hope that centers with scarce MRI table time availability can provide an alternative characterization with comparable predictive value.

Nick Pannoni , 62, renal cell carcinoma (kidney cancer), Forestdale, with Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology, Dana-Farber

Anne Gross, PHD, RN, Senior Vice President and Chief Nursing Officer, Dana-Farber● Anne Gross, PhD, RN is senior vice president for patient care services and chiefnursing officer. There are more than 700 registered nurses, nurse practitioners,clinical specialists, and nurse scientists working at Dana-Farber.● Anne can give insight into the challenges overcome by the amazing nursing staffduring the COVID pandemic. What they have done and achieved since 2020 inspiresher and keeps her optimistic for the future.● She can also provide insight about the often emotionally powerful relationshipnurses form with patients and why it's a unique nursing career.● Since 2020, along with continuing to provide cancer treatment, oncology nurses hadthe added challenge of protecting patients and each other from COVID hrough strictisolation procedures and the use of personal protective equipment (also known asPPE).● The nurse acquired new skills to care for immunocompromised patients in specialCOVID intensive care units.● In other settings, oncology nurse navigators transitioned their practice to be remoteso they could care for patients while they were in their homes through telehealthvisits and clinical trial nurses innovated standard operations, such as shippinginvestigational drugs to patients' homes, to enable them to safely remain on theirstudies.● Anne takes great pride in Dana-Farber's nursing and patient care services staff andthe patient experience at Dana-Farber remains as strong as ever: As a patient youare never alone.● Anne leads a nursing staff focused on the future:○ Continuing to manage through the lingering threats of the pandemic whilefocusing on building a pipeline for the future○ Addressing the national nursing shortage with the goal of training the nextgeneration of oncology nurses ○ Expanding access to our care by opening Foxborough location and expandingSouth Shore Nick Pannoni (PAH-NO-NEE), 62, renal cell carcinoma (kidney cancer), Forestdale, with Dr. ToniChoueiri (SHWERRY), Director of the Lank Center for Genitourinary Oncology, Dana-Farber● Six years ago, Nick, a father of four, was diagnosed with prostate cancer, but it wascaught early enough where doctors only needed to remove his prostate for him to bedeclared cancer-free.● Unfortunately, three years later, cancer had returned, but this time it was acompletely different type of cancer: kidney cancer. Specifically known as renal cellcarcinoma, Nick's left kidney was removed as it had been encased in the cancer.● Once Nick recovered, his oncologist Dr. Steven Chang mentioned that he may wantto see Dr. Toni Choueiri, the lead author of the KEYTRUDA study.● Nick entered the clinical trial as a double-blind participant, meaning he would notknow if he received the medication or a placebo. Though there isn't a way to know for sure, Nick believes he received the drug as he experienced several of thecommon side effects.● Once high-risk, there is now no evidence of disease. Nick continues to move forwardand live his everyday life. He gets blood work and scans every four months, but onlyto make sure that cancer has not come back.